IFP Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-10,050
| Closed | -$479K | – | 4638 |
|
|
2022
Q4 | $479K | Buy |
10,050
+50
| +0.5% | +$33 | 0.01% | 909 |
|
|
2022
Q3 | $477K | Buy |
+10,000
| New | +$15.6K | 0.01% | 955 |
|
|
2021
Q3 | – | Sell |
-350
| Closed | -$2K | – | 3495 |
|
|
2021
Q2 | $2K | Hold |
350
| – | – | ﹤0.01% | 2808 |
|
|
2021
Q1 | $2K | Buy |
+350
| New | +$2.35K | ﹤0.01% | 2741 |
|
|
2019
Q4 | – | Sell |
-190
| Closed | -$1.38K | – | 3202 |
|
|
2019
Q3 | $1K | Buy |
+190
| New | +$1.54K | ﹤0.01% | 2971 |
|
|
2019
Q1 | – | Sell |
-250
| Closed | -$4K | – | 3644 |
|
|
2018
Q4 | $4K | Buy |
+250
| New | +$5.11K | ﹤0.01% | 2978 |
|
|
2018
Q2 | – | Sell |
-400
| Closed | -$27K | – | 4122 |
|
|
2018
Q1 | $27K | Hold |
400
| – | – | ﹤0.01% | 2208 |
|
|
2017
Q4 | $27K | Sell |
400
-850
| -68% | -$59.4K | ﹤0.01% | 2236 |
|
|
2017
Q3 | $103K | Sell |
1,250
-155
| -11% | -$12.3K | ﹤0.01% | 1542 |
|
|
2017
Q2 | $132K | Sell |
1,405
-1,705
| -55% | -$104K | 0.01% | 1379 |
|
|
2017
Q1 | $198K | Sell |
3,110
-965
| -24% | -$58.7K | 0.01% | 1118 |
|
|
2016
Q4 | $181K | Sell |
4,075
-4,100
| -50% | -$144K | 0.01% | 1110 |
|
|
2016
Q3 | $295K | Buy |
8,175
+2,175
| +36% | +$46.7K | 0.02% | 818 |
|
|
2016
Q2 | $82K | Buy |
+6,000
| New | +$87.7K | ﹤0.01% | 1461 |
|
|
2016
Q1 | – | Sell |
-1,250
| Closed | -$44K | – | 3638 |
|
|
2015
Q4 | $44K | Buy |
+1,250
| New | +$80.6K | ﹤0.01% | 1695 |
|
Other funds holding CLVS
IFP Advisors's CLVS Position: Q1 2023 in Review
IFP Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q1 2023, closing a stake of 10,050 shares — an estimated $479K sold.
IFP Advisors first reported a position in CLVS in Q4 2015 and held it in 15 quarters. The position peaked at $479K in Q4 2022. 2 funds tracked by Wall St. Rank hold CLVS as of Q1 2023.
- IFP Advisors reported no remaining Clovis Oncology, Inc. position as of Q1 2023 after selling out during the quarter.
- IFP Advisors sold 10,050 Clovis Oncology, Inc. shares in Q1 2023, an estimated $479K.
- IFP Advisors first reported a position in Clovis Oncology, Inc. in Q4 2015 and held it in 15 quarters.
- IFP Advisors's Clovis Oncology, Inc. position peaked at $479K in Q4 2022.
- 2 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2023.
Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.